R&D Biotech strategy and nanomedicine: the pharmaphorum podcast For episode 5 of the pharmaphorum podcast Dominic Tyer met Blueberry Therapeutics’ CEO Dr John Ridden at The Wellcome Coll
Events Partner Content NANO.IL.2018, the leading international nanotechnology confe... NANO.IL.2018 conference & exhibition
Views & Analysis Nanomedicine: delivering on its promise? The nanomedicines market is worth billions. Tarun Pandotra reviews developments in the sector.
News Ultragenyx to slash costs after Angelman trial failure Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
